These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 17418218)

  • 21. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease.
    Diehm C; Allenberg JR; Pittrow D; Mahn M; Tepohl G; Haberl RL; Darius H; Burghaus I; Trampisch HJ;
    Circulation; 2009 Nov; 120(21):2053-61. PubMed ID: 19901192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.
    Higgins P; Walters MR; Murray HM; McArthur K; McConnachie A; Lees KR; Dawson J
    Heart; 2014 Jul; 100(14):1085-92. PubMed ID: 24790069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
    ; Catalano M; Born G; Peto R
    J Intern Med; 2007 Mar; 261(3):276-84. PubMed ID: 17305650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
    Stone WM; Demaerschalk BM; Fowl RJ; Money SR
    J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ankle brachial pressure index but not brachial-ankle pulse wave velocity is a strong predictor of systemic atherosclerotic morbidity and mortality in patients on maintenance hemodialysis.
    Tanaka M; Ishii H; Aoyama T; Takahashi H; Toriyama T; Kasuga H; Takeshita K; Yoshikawa D; Amano T; Murohara T
    Atherosclerosis; 2011 Dec; 219(2):643-7. PubMed ID: 22018643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study.
    Sprengers RW; Janssen KJ; Moll FL; Verhaar MC; van der Graaf Y;
    J Vasc Surg; 2009 Dec; 50(6):1369-76. PubMed ID: 19837547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomes.
    Nehler MR; Brass EP; Anthony R; Dormandy J; Jiao J; McNamara TO; Hiatt WR;
    J Vasc Surg; 2007 May; 45(5):953-60; discussion 960-1. PubMed ID: 17350216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
    Bonaca MP; Scirica BM; Braunwald E; Wiviott SD; Goto S; Nilsen DW; Bonarjee V; Murphy SA; Morrow DA
    J Am Coll Cardiol; 2014 Dec; 64(22):2318-26. PubMed ID: 25465417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases-a large-scale, randomized, placebo controlled trial].
    Liu LS; Gong LS; Wang W;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Jul; 33(7):613-7. PubMed ID: 16080808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion.
    Vammen S; Lindholt JS; Ostergaard L; Fasting H; Henneberg EW
    Br J Surg; 2001 Aug; 88(8):1066-72. PubMed ID: 11488791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of roxithromycin treatment on the endothelial function of Chlamydia pneumoniae seropositive men suffering from peripheral arterial occlusive disease.
    Wiesli P; Schulthess G
    Circulation; 2002 Dec; 106(25):e226; author reply e226. PubMed ID: 12485976
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.
    Feringa HH; Karagiannis SE; van Waning VH; Boersma E; Schouten O; Bax JJ; Poldermans D
    J Vasc Surg; 2007 May; 45(5):936-43. PubMed ID: 17360142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis.
    Woessner R; Grauer MT; Frese A; Bethke F; Ginger T; Hans A; Treib J
    Infection; 2006 Dec; 34(6):342-4. PubMed ID: 17180590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial.
    Høgh A; Vammen S; Ostergaard L; Joensen JB; Henneberg EW; Lindholt JS
    Vasc Endovascular Surg; 2009; 43(5):452-6. PubMed ID: 19640922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors.
    Feringa HH; Karagiannis SE; Chonchol M; Vidakovic R; Noordzij PG; Elhendy A; van Domburg RT; Welten G; Schouten O; Bax JJ; Berl T; Poldermans D
    J Am Soc Nephrol; 2007 Jun; 18(6):1872-9. PubMed ID: 17475817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index.
    Brevetti G; Silvestro A; Schiano V; Chiariello M
    Circulation; 2003 Oct; 108(17):2093-8. PubMed ID: 14530195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of peripheral arterial disease on in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction.
    Jeremias A; Gruberg L; Patel J; Connors G; Brown DL
    Am J Cardiol; 2010 May; 105(9):1268-71. PubMed ID: 20403477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.
    Muhlestein JB; Anderson JL; Carlquist JF; Salunkhe K; Horne BD; Pearson RR; Bunch TJ; Allen A; Trehan S; Nielson C
    Circulation; 2000 Oct; 102(15):1755-60. PubMed ID: 11023928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.